1. Home
  2. FIHL vs EVO Comparison

FIHL vs EVO Comparison

Compare FIHL & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FIHL
  • EVO
  • Stock Information
  • Founded
  • FIHL 2014
  • EVO 1993
  • Country
  • FIHL Bermuda
  • EVO Germany
  • Employees
  • FIHL N/A
  • EVO N/A
  • Industry
  • FIHL
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FIHL
  • EVO Health Care
  • Exchange
  • FIHL Nasdaq
  • EVO Nasdaq
  • Market Cap
  • FIHL 1.8B
  • EVO 1.5B
  • IPO Year
  • FIHL 2023
  • EVO 2021
  • Fundamental
  • Price
  • FIHL $16.19
  • EVO $4.08
  • Analyst Decision
  • FIHL Hold
  • EVO Buy
  • Analyst Count
  • FIHL 7
  • EVO 2
  • Target Price
  • FIHL $20.29
  • EVO $5.90
  • AVG Volume (30 Days)
  • FIHL 810.6K
  • EVO 116.5K
  • Earning Date
  • FIHL 08-13-2025
  • EVO 08-13-2025
  • Dividend Yield
  • FIHL 2.47%
  • EVO N/A
  • EPS Growth
  • FIHL N/A
  • EVO N/A
  • EPS
  • FIHL N/A
  • EVO N/A
  • Revenue
  • FIHL $2,558,400,000.00
  • EVO $851,944,444.00
  • Revenue This Year
  • FIHL $24.21
  • EVO $10.08
  • Revenue Next Year
  • FIHL $5.09
  • EVO $10.99
  • P/E Ratio
  • FIHL N/A
  • EVO N/A
  • Revenue Growth
  • FIHL 23.93
  • EVO 1.50
  • 52 Week Low
  • FIHL $14.17
  • EVO $2.84
  • 52 Week High
  • FIHL $21.32
  • EVO $5.64
  • Technical
  • Relative Strength Index (RSI)
  • FIHL 45.88
  • EVO 57.98
  • Support Level
  • FIHL $16.15
  • EVO $4.15
  • Resistance Level
  • FIHL $16.98
  • EVO $4.35
  • Average True Range (ATR)
  • FIHL 0.45
  • EVO 0.11
  • MACD
  • FIHL 0.02
  • EVO 0.03
  • Stochastic Oscillator
  • FIHL 46.76
  • EVO 98.39

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: